Price$2.18-0.24 (-10.10%)
01:30 PM07:45 PM
News · 26 weeks46-8%
2025-10-262026-04-19
Mix3090d
- SEC Filings10(33%)
- Other9(30%)
- Analyst6(20%)
- Insider4(13%)
- Offering1(3%)
Latest news
25 items- ANALYSTOppenheimer initiated coverage on Equillium with a new price targetOppenheimer initiated coverage of Equillium with a rating of Outperform and set a new price target of $7.00
- PREquillium to Participate in Oppenheimer's 2026 Innovation on the Island EventLA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer's 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon recepto
- SECSEC Form EFFECT filed by Equillium Inc.EFFECT - Equillium, Inc. (0001746466) (Filer)
- ANALYSTB. Riley Securities initiated coverage on Equillium with a new price targetB. Riley Securities initiated coverage of Equillium with a rating of Buy and set a new price target of $6.00
- SECSEC Form DEFA14A filed by Equillium Inc.DEFA14A - Equillium, Inc. (0001746466) (Filer)
- SECSEC Form DEF 14A filed by Equillium Inc.DEF 14A - Equillium, Inc. (0001746466) (Filer)
- ANALYSTRaymond James initiated coverage on Equillium with a new price targetRaymond James initiated coverage of Equillium with a rating of Strong Buy and set a new price target of $6.00
- PREquillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of ImmunologistsLA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026. "We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration," said Dr. Stephen Connelly, Chief Scientific Officer of Equil
- SECSEC Form S-3 filed by Equillium Inc.S-3 - Equillium, Inc. (0001746466) (Filer)
- ANALYSTCantor Fitzgerald initiated coverage on Equillium with a new price targetCantor Fitzgerald initiated coverage of Equillium with a rating of Overweight and set a new price target of $10.00
- PREquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $2.04, Eq
- SECSEC Form PRE 14A filed by Equillium Inc.PRE 14A - Equillium, Inc. (0001746466) (Filer)
- SECSEC Form EFFECT filed by Equillium Inc.EFFECT - Equillium, Inc. (0001746466) (Filer)
- SECSEC Form S-8 filed by Equillium Inc.S-8 - Equillium, Inc. (0001746466) (Filer)
- SECSEC Form 10-K filed by Equillium Inc.10-K - Equillium, Inc. (0001746466) (Filer)
- SECEquillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical HighlightsInitiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029 LA JOLLA, Calif, March 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its fourth quarter and fiscal year ended December 31, 2025. "2025 was a transformative year as we sharpened our strategic focus on EQ504 and strengthened our financia
- SECSEC Form SCHEDULE 13G filed by Equillium Inc.SCHEDULE 13G - Equillium, Inc. (0001746466) (Subject)
- PREquillium to Participate in the 38th Annual Roth ConferenceLA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a potent
- INSIDERSr. Vice President and COO Zedelmayer Christine exercised 120,312 shares at a strike of $0.79 and sold $300,816 worth of shares (120,312 units at $2.50) (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)
- ANALYSTRoth Capital initiated coverage on Equillium with a new price targetRoth Capital initiated coverage of Equillium with a rating of Buy and set a new price target of $12.00
- SECEquillium Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Equillium, Inc. (0001746466) (Filer)
- PREquillium Announces $35 Million Financing with RA Capital ManagementCapital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. ("Equillium" or the "Company") (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will provide approximately $35 million in gross proceeds to Equillium. Pursuant to the terms of the securities purchase agreement, the Company will issue approximately
- INSIDERAmendment: Sr. Vice President and COO Zedelmayer Christine exercised 185,937 shares at a strike of $0.76 and sold $328,104 worth of shares (185,937 units at $1.76) (SEC Form 4)4/A - Equillium, Inc. (0001746466) (Issuer)
- INSIDERSr. Vice President and COO Zedelmayer Christine exercised 152,361 shares at a strike of $0.79 and sold $362,438 worth of shares (181,219 units at $2.00), decreasing direct ownership by 32% to 62,586 units (SEC Form 4)4 - Equillium, Inc. (0001746466) (Issuer)